Vamil Divan
Stock Analyst at Guggenheim
(4.80)
# 78
Out of 5,072 analysts
242
Total ratings
66.09%
Success rate
21.84%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Buy | $33 → $35 | $25.71 | +36.13% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $12.48 | +36.22% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.55 | +416.13% | 1 | Nov 18, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $114 → $115 | $84.36 | +36.32% | 13 | Nov 10, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.68 | +342.35% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $227.66 | +6.30% | 28 | Oct 20, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $167 → $206 | $207.56 | -0.75% | 17 | Sep 23, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $5.36 | +105.22% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $9.54 | +36.27% | 2 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Buy | $125 → $172 | $204.51 | -15.90% | 7 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $37.03 | +5.32% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.12 | +230.19% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $288 | $344.57 | -16.42% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $6.30 | +852.38% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $104.63 | +9.91% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $36.26 | +29.62% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.09 | +223.62% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $33.33 | +83.02% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $17.50 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $4.19 | +520.53% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.34 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $24.81 | -23.42% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $151.58 | -35.35% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $29.72 | +14.40% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.37 | +321.94% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $150.98 | -67.55% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,104.34 | -67.76% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $7.18 | -16.43% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $9.48 | +1,524.47% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $7.04 | +113.07% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.13 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $26.32 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $9.07 | +65.38% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $49.25 | +23.86% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.95 | +2,507.59% | 3 | Jan 17, 2018 |
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $25.71
Upside: +36.13%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $12.48
Upside: +36.22%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.55
Upside: +416.13%
ANI Pharmaceuticals
Nov 10, 2025
Maintains: Buy
Price Target: $114 → $115
Current: $84.36
Upside: +36.32%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.68
Upside: +342.35%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $227.66
Upside: +6.30%
Johnson & Johnson
Sep 23, 2025
Upgrades: Buy
Price Target: $167 → $206
Current: $207.56
Upside: -0.75%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.36
Upside: +105.22%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $9.54
Upside: +36.27%
Insmed
Sep 8, 2025
Maintains: Buy
Price Target: $125 → $172
Current: $204.51
Upside: -15.90%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $37.03
Upside: +5.32%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.12
Upside: +230.19%
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $344.57
Upside: -16.42%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $6.30
Upside: +852.38%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $104.63
Upside: +9.91%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $36.26
Upside: +29.62%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.09
Upside: +223.62%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $33.33
Upside: +83.02%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $17.50
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $4.19
Upside: +520.53%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $3.34
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $24.81
Upside: -23.42%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $151.58
Upside: -35.35%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $29.72
Upside: +14.40%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.37
Upside: +321.94%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $150.98
Upside: -67.55%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,104.34
Upside: -67.76%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $7.18
Upside: -16.43%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $9.48
Upside: +1,524.47%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $7.04
Upside: +113.07%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $31.13
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $26.32
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $9.07
Upside: +65.38%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $49.25
Upside: +23.86%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.95
Upside: +2,507.59%